Measles-containing vaccines and febrile seizures in children age 4 to 6 years

Pediatrics

Volumn 129, Issue 5, 2012, Pages 809-814

  Klein, Nicola P ^a   Lewis, Edwin ^a   Baxter, Roger ^a   Weintraub, Eric ^b   Glanz, Jason ^a,c   Naleway, Allison ^a   Jackson, Lisa A ^d   Nordin, James ^e   Lieu, Tracy ^f,g   Belongia, Edward A ^h   Fireman, Bruce ^a  

^a KAISER PERMANENTE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Global Health and Health Disparities   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h MARSHFIELD CLINIC   (United States)

Author keywords

Fever; Measles; Seizures; Vaccine; Varicella

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; CHICKENPOX; CHILD; DRUG SAFETY; EMERGENCY WARD; FEBRILE CONVULSION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MASS IMMUNIZATION; MEASLES; MEDICAL RECORD REVIEW; MUMPS; OUTPATIENT DEPARTMENT; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; REASSURANCE; RUBELLA;

EID: 84860595928     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-3198     Document Type: Article

References (15)

1. Belongia EA, Irving SA, Shui IM, et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J. 2010;29:1-5
2. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(10 suppl 2):S89-S95
3. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine. 2009;27(32):4257-4262
4. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine. MMWR Morb Mortal Wkly Rep. 2008;57(10):258-260
5. LeBaron CW, Bi D, Sullivan BJ, Beck C, Gargiullo P. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine. Pediatrics. 2006;118(4):1422-1430 (Pubitemid 46393787)
6. Klein NP, Fireman B, Yih WK, et al Vaccine Safety Datalink. Measles-mumps-rubellavaricella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1). Available at: www.pediatrics.org/cgi/content/ full/126/1/e1
7. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656-4661
8. Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(rr-3):1-12
9. Davis RL, Marcuse E, Black S, et al The Vaccine Safety Datalink Team. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. Pediatrics. 1997;100(5):767-771 (Pubitemid 27463311)
10. Gillet Y, Steri GC, Behre U, et al. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Vaccine. 2009;27(3):446-453
11. Esteghamati A, Keshtkar A, Heshmat R, et al. Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran. Arch Iran Med. 2011;14(2):91-95
12. Reid AY, Galic MA, Teskey GC, Pittman QJ. Febrile seizures: current views and investigations. Can J Neurol Sci. 2009;36(6):679-686
13. Reisinger KS, Brown ML, Xu J, et al; Protocol 014 Study Group for ProQuad. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax. Pediatrics. 2006;117(2):265-272 (Pubitemid 46071587)
14. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J. 2007;26(2):153-158 (Pubitemid 46183366)
15. Halperin SA, Ferrera G, Scheifele D, et al. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine. 2009;27(20):2701-2706